LeMaitre Vascular posted Q1 2026 sales of $66.6 million, up 11% year-over-year, driven by strong product sales and geographic expansion. Gross margin improved to 72.7%, and operating income rose 41% to $17.8 million, resulting in a 42% increase in earnings per share to $0.68. The company declared a quarterly dividend of $0.25 per share and announced a $100 million share repurchase program. For 2026, LeMaitre expects 12% sales growth and 26% adjusted EPS growth, reflecting continued operational leverage and market expansion.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
The Dolphin Company's current management proposed selling its main assets in Mexico to Delphinus Blue Planet, a Grupo Xcaret subsidiary, for $20 million. This deal would give Delphinus control over more than 90% of dolphin habitats in Mexico, creatin...
Agility Robotics, backed by Humanoid Global, is set to go public in 2026 via a merger with Churchill Capital Corp XI, valuing the company at $2.5 billion and raising over $620 million. The funds will support scaling production of its Digit v5 humanoi...
The London Company Mid Cap portfolio returned 9.7% (9.5% net) in the second quarter, underperforming the Russell Midcap Index which rose 13.8%. The market gains were driven mainly by momentum and high-beta stocks, with the top beta quintile returning...
The US Senate Commerce Committee advanced legislation that would ban the sale of connected vehicles in the US by companies with more than 15% Chinese ownership, potentially affecting Mercedes-Benz, which has nearly 20% Chinese investor stakes. The bi...
